FDAnews
www.fdanews.com/articles/101008-allos-to-study-rh1-in-patients-with-tumors-or-nhl

Allos to Study RH1 in Patients With Tumors or NHL

November 13, 2007

Allos Therapeutics has started patient enrollment in a nonrandomized, open-label, multicenter, dose-escalation Phase I study of the targeted chemotherapeutic agent RH1 in patients with advanced solid tumors or non-Hodgkin’s lymphoma (NHL).

In the study, patients will receive a three-hour intravenous infusion of RH1 administered once every 21 days. The dosage will start at 1.5 mg/m2, and the doses will increase in subsequent cohorts.

Up to 60 patients will enroll in the study to determine the maximum tolerated dose, and three to six patients will be in each group, Allos said.